PDSB logo

PDS Biotechnology (PDSB) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 September 2015

Indexes:

Not included

Description:

PDS Biotechnology is a biopharmaceutical company focused on developing innovative cancer therapies. They use their proprietary technology to create personalized treatments that stimulate the immune system to fight tumors. Their goal is to improve patient outcomes and provide new options for cancer care.

Events Calendar

Earnings

Next earnings date:

Mar 27, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Mar 18, 2019

Analyst ratings

Recent major analysts updates

18 Dec '24 HC Wainwright & Co.
Buy
25 Nov '24 B. Riley Securities
Buy
15 Nov '24 HC Wainwright & Co.
Buy
24 Oct '24 HC Wainwright & Co.
Buy
02 Oct '24 HC Wainwright & Co.
Buy
17 Sept '24 HC Wainwright & Co.
Buy
20 Aug '24 Alliance Global Partners
Buy
01 Aug '24 HC Wainwright & Co.
Buy
12 June '24 HC Wainwright & Co.
Buy
12 June '24 B. Riley Securities
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
PDSB
zacks.com20 November 2024

The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
PDSB
seekingalpha.com14 November 2024

PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Ali Rashidfarrokhi - B. Riley Robert LeBoyer - Noble Capital Markets Operator Good morning ladies and gentlemen and welcome to PDS Biotech's Third Quarter 2024 Results and Clinical Strategy Update Conference Call.

PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
PDSB
zacks.com22 October 2024

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
PDSB
Seeking Alpha27 March 2024

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript

All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
PDSB
Zacks Investment Research02 January 2024

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript
PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript
PDSB
Seeking Alpha14 November 2023

PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Nicole Jones - Investor Relations Frank Bedu-Addo - Chief Executive Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Joe Pantginis - HC Wainwright Laura Suriel - Alliance Resource Partners Operator Greetings and welcome to the PDS Biotechnology Third Quarter 2023 Earnings Call and Webcast.

PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
PDSB
Zacks Investment Research29 August 2023

Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.

PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
PDSB
Seeking Alpha14 August 2023

PDS Biotechnology has achieved positive results in its phase 2 study of PDS0101 in combination with Merck's Keytruda for HPV16-positive head and neck cancer. The interim analysis showed 9 confirmed responses, which increased to 14 in a later update, surpassing the efficacy threshold for the study. PDS plans to submit an amended IND application to the FDA in Q3 2023 to initiate its phase 3 VERSATILE-003 study.

The Prognosis For PDS Biotechnology
The Prognosis For PDS Biotechnology
The Prognosis For PDS Biotechnology
PDSB
Seeking Alpha13 August 2023

PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeline and is well-liked within the analyst firm community. With two registrational studies on the horizon, it seems a good time to 'circle back' on this small developmental, oncology-focused concern.

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
PDSB
GlobeNewsWire05 June 2023

FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will be hosting a conference call and webcast tomorrow, June 6, 2023, to discuss the promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), presented at the 2023 American Society for Clinical Oncology (ASCO) meeting.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of PDS Biotechnology?
  • What is the ticker symbol for PDS Biotechnology?
  • Does PDS Biotechnology pay dividends?
  • What sector is PDS Biotechnology in?
  • What industry is PDS Biotechnology in?
  • What country is PDS Biotechnology based in?
  • When did PDS Biotechnology go public?
  • Is PDS Biotechnology in the S&P 500?
  • Is PDS Biotechnology in the NASDAQ 100?
  • Is PDS Biotechnology in the Dow Jones?
  • When was PDS Biotechnology's last earnings report?
  • When does PDS Biotechnology report earnings?
  • Should I buy PDS Biotechnology stock now?

What is the primary business of PDS Biotechnology?

PDS Biotechnology is a biopharmaceutical company focused on developing innovative cancer therapies. They use their proprietary technology to create personalized treatments that stimulate the immune system to fight tumors. Their goal is to improve patient outcomes and provide new options for cancer care.

What is the ticker symbol for PDS Biotechnology?

The ticker symbol for PDS Biotechnology is NASDAQ:PDSB

Does PDS Biotechnology pay dividends?

No, PDS Biotechnology does not pay dividends

What sector is PDS Biotechnology in?

PDS Biotechnology is in the Healthcare sector

What industry is PDS Biotechnology in?

PDS Biotechnology is in the Biotechnology industry

What country is PDS Biotechnology based in?

PDS Biotechnology is headquartered in United States

When did PDS Biotechnology go public?

PDS Biotechnology's initial public offering (IPO) was on 30 September 2015

Is PDS Biotechnology in the S&P 500?

No, PDS Biotechnology is not included in the S&P 500 index

Is PDS Biotechnology in the NASDAQ 100?

No, PDS Biotechnology is not included in the NASDAQ 100 index

Is PDS Biotechnology in the Dow Jones?

No, PDS Biotechnology is not included in the Dow Jones index

When was PDS Biotechnology's last earnings report?

PDS Biotechnology's most recent earnings report was on 14 November 2024

When does PDS Biotechnology report earnings?

The next expected earnings date for PDS Biotechnology is 27 March 2025

Should I buy PDS Biotechnology stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions